Drug Trial Radar · NCT07131059
MRD-positive AML Clinical Study
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
537
Planned (sponsor's estimate)
Start
May 11, 2024
Primary completion
May 10, 2028
Study completion Oct 30, 2028
Sponsor
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 20, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the following drugs and protocols: Chemotherapy, small molecule targeted drugs, demethylation drugs, liposome drugs and the combination of these drugs to form a combination of treatment regimen, the specific treatment regimen will be updated according to the results of this trial and the latest research progress at home and abroad.
Conditions
- AML, Adult
Interventions
IvosidenibDrug
500mg d1-28
GilteritinibDrug
120mg d1-28
VenetoclaxDrug
400mg d1-21 ; 400mg d1-7; 400mg d1-28; 600mg d1-14
AvapritinibDrug
200mg d1-28.
DaunorubicinDrug
45mg/m2/d d1-2;
CytarabineDrug
100mg/m2/d d1-5
IdarubicinDrug
10mg/m2/d d1-2
MitoxantroneDrug
8mg/m2/d d1-2
HomoharringtonineDrug
2mg/m2/d d1-5
AzacitidineDrug
75mgd/m2 d1-7.
RuxolitinibDrug
20 mg twice daily, 28-day cycle
TrametinibDrug
12 mg twice daily, 28-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- relapse-free survival rateTime frame: up to 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Blood Diseases Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.